01.06.2022 • News

Bakelite Synthetics Buys Georgia-Pacific Chemicals

Bakelite Synthetics – formerly part of US resins producer Hexion – has closed its purchase of Georgia-Pacific Chemicals. Financial terms were not disclosed.

The acquisition gives Bakelite complementary resin and formaldehyde technology and end markets in the building materials, transportation, industrial, chemical intermediate and specialty resins space, as well as 11 chemical facilities employing about 600 people in the US and South America.

“We are excited about the opportunities that will result from the combined strengths of the two companies,” said Bakelite CEO JP Aucoin. “This acquisition enables us to deliver greater value to our customers through a broader product offering and expanded geographic reach. It also enables us to deliver on significant organic growth with the strong tailwinds in US residential construction.”

The combined company’s new headquarters will be based in Atlanta, Georgia – Bakelite’s former base was in Louisville, Kentucky – and will consist of approximately 1,500 employees and 21 manufacturing sites in 10 countries.

Bakelite was formed on May 1, 2021, from the $425 million purchase of Hexion’s phenolic resins business by private equity firms Black Diamond and Investindustrial.

Author: Elaine Burridge, Freelance Journalist

Photo by Patrick Schätz on Unsplash
Photo by Patrick Schätz on Unsplash

Company

Logo:

Bakelite Synthetics

1040 Crown Pointe Parkway
30338 Atlanta
US

Company contact







Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read